Drugs / BI 3802876
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06081530 | Oct 2023 → Mar 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07325526 | Feb 2026 → Jun 2027 expected | cirrhosis of liver | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3802876 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06081530 ↗ |
| Route | Intravenous | “Intravenous BI 3802876” NCT06081530 ↗ |